Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03267264 · ClinicalTrials.gov registry record · NA
Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen Needle
A NA study, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- NA
- Development phase
- 248
- Enrollment target
NCT03267264 is a NA study that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 248 participants.
The verdict
NCT03267264, a NA study, has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 248 participants
- Enrollment target
Study Summary
This is a multi-site, prospective, open-label, randomized, 2 period cross over study comparing the subjects' current 32G pen needle (four groups of pen needles) to the BD Nucleus pen needle. The study will consist of two 15 day periods ( in which the subject will use each pen needle \[BD Nucleus pen needle or subject's current pen needle, order randomized\] for injection. At the end of the last study period, each subject will be asked to evaluate his or her perceptions using a 150mm relative VAS scale.
Interventions
- DEVICE BD Nano™ vs Nucleus
- DEVICE NovoFine® vs Nucleus
- DEVICE NovoTwist®/NovoFine® Plus vs Nucleus
- DEVICE Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2018-05-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03267264
The ClinicalTrials.gov registry entry for NCT03267264 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Becton, Dickinson and Company, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BD Nano™ vs Nucleus is the first listed.
NCT03267264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03267264 about?
NCT03267264 is a clinical study titled "Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen Needle". This is a multi-site, prospective, open-label, randomized, 2 period cross over study comparing the subjects' current 32G pen needle (four groups of pen needles) to the BD Nucleus pen needle. The study will consist of two 15 day periods ( in which the subject will use each pen needle \[BD Nucleus pen...
What is the current status of trial NCT03267264?
This trial is currently completed. It is a NA study. The enrollment target is 248 participants. The study started on 2017-09-01. Estimated completion is 2018-05-24.
What interventions are being tested in trial NCT03267264?
The interventions under investigation include: BD Nano™ vs Nucleus (DEVICE), NovoFine® vs Nucleus (DEVICE), NovoTwist®/NovoFine® Plus vs Nucleus (DEVICE), Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus (DEVICE).
Who is sponsoring clinical trial NCT03267264?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.